GNA13

Across TCGA pan-cancer cohorts, GNA13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GNA13 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher GNA13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNA13 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where GNA13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.529	0.862	.006	18	view →
LUAD	DFS	Median	All	0.982	0.852	.003	12	view →
PDAC	DFS	Tertile	All	0.730	0.943	.001	7	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.194	.011	5	view →
LSCC	DFS	Quartile	III,IV	0.878	0.310	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GNA13–GBM (DFS)

Open the GBM breakdown →